Recent application of analytical methods to phase I and phase II drugs development: A review

Biomedical Chromatography

Volumn 26, Issue 3, 2012, Pages 283-300

  Locatelli, Marcello ^a   Governatori, Luciana ^a   Carlucci, Giuseppe ^a   Genovese, Salvatore ^a   Mollica, Adriano ^a   Epifano, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Analysis; Analytical chemistry; Analytical method; High throughput technologies; Hyphenated techniques; Legislation; Mass spectrometry; Natural products; Phase I and phase II drug development; Therapeutic drug monitoring

Indexed keywords

DISSOCIATION; DRUG PRODUCTS; PATIENT MONITORING;

ANALYSE; ANALYTICAL METHOD; DRUG DEVELOPMENT; HIGH THROUGHPUT TECHNOLOGY; HYPHENATED TECHNIQUES; NATURAL PRODUCTS; PHASE I; PHASE I AND PHASE II DRUG DEVELOPMENT; PHASE II; THERAPEUTIC DRUG MONITORING;

MASS SPECTROMETRY;

ALIZAPRIDE; AMFEBUTAMONE; ANANDAMIDE; ANTHRACYCLINE; BACITRACIN; BETAMETHASONE; CEPHALOSPORIN; DEHYDRODIDEMNIN B; DIURETIC AGENT; GROWTH HORMONE; IBUPROFEN; LERCANIDIPINE; LISINOPRIL; LORATADINE; MEDROXYPROGESTERONE; METFORMIN; MOXIFLOXACIN; NEVIRAPINE; NIMESULIDE; PARACETAMOL; PENICILLAMINE; RANITIDINE; RESISTIN; ROPINIROLE; TERPENOID; TETRACYCLINE; TIMOLOL; UNINDEXED DRUG; VINPOCETINE; XANTHONE 4 ACETIC ACID;

ANALYTIC METHOD; BODY FLUID; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LAW; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TANDEM MASS SPECTROMETRY;

EID: 84856561988     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1674     Document Type: Review

References (193)

1. Acar C, Teksöz S, Ünak P and Biber FZ. Investigation of new bifunctional agents: d-penicillamine. Journal of Radioanalytical and Nucluear Chemistry 2007; 273: 641-647.
2. Ahuja S. Overview of capillary electrophoresis in pharmaceutical analysis. Separation Science Technology 2008; 9: 1-8.
3. Alsenz J and Manfred K. High throughput solubility measurement in drug discovery and development. Advances in Drug Delivery Review 2007; 59: 546-567.
4. Altria KD, Chen AB and Clohs L. Capillary electrophoresis as a routine analytical tool in pharmaceutical analysis. LCGC 2001; 19: 972-985.
5. Anastos N, Barnett NW and Lewis SW. Capillary electrophoresis for forensic drug analysis: a review. Talanta 2005; 67: 269-279.
6. Anstead GM, Carlson KE and Katzenellenbogen JA. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997; 62: 268-303.
7. Ascalone V, Flaminio L, Guinebault P, Thénot JP and Morselli PL. Determination of zolpidem, a new sleep-inducing agent, and its metabolites in biological fluids: pharmacokinetics, drug metabolism and overdosing investigations in humans. Journal of Chromatography B: Biomedical Science Application 1992; 581: 237-250.
8. Atterwill CK and Wing MG. In vitro preclinical lead optimization technologies (PLOTs) in pharmaceutical development. Toxicology Letters 2002; 127: 143-151.
9. Atul BV, Paliwal JK and Gupta RC. Development and validation of a new high-performance liquid chromatographic assay of centpropazine, a new antidepressant compound, in serum. Journal of Pharmaceutical and Biomedical Analysis 1999; 20: 449-457.
10. a values of active pharmaceutical ingredients. Trends in Analytical Chemistry 2007; 26: 1043-1061.
11. Bakshi M and Singh S. Development of validated stability-indicating assay methods - critical review. Journal of Pharmaceutical and Biomedical Analysis 2002; 28: 1011-1040.
12. Bala I, Bhardwaj V, Hariharan S and Ravi Kumar MNV. Analytical methods for assay of ellagic acid and its solubility studies. Journal of Pharmaceutical and Biomedical Analysis 2006; 40: 206-210.
13. Balunas MJ and Kinghorn AD. Drug discovery from medical plants. Life Science 2005; 78: 431-441.
14. Becher F, Pruvost A, Clement G, Tabet JC and Ezan E. Quantification of small therapeutic proteins in plasma by liquid chromatography-tandem mass spectrometry: application to an elastase inhibitor EPI-hNE4. Analytical Chemistry 2006; 78: 2306-2313.
15. Bellmann-Sickert K and Beck-Sickinger AG. Peptide drugs to target G protein-coupled receptors. Trends in Pharmacology Science 2010; 31: 434-441.
16. Berlin JM and Ellenberg SS. Inclusion of women in clinical trials. BMC Medicine 2009; 7: 56-58.
17. Bharathi C, Prabahar K, Prasad CS, Kumar SM, Magesh S, Handa VK, Dandala R and Naidu A. Impurity profile study of zaleplon. Journal of Pharmaceutical and Biomedical Analysis 2007; 44: 101-109.
18. Blanco-Príeto MJ, Campanero MA, Besseghir K, Heimgatner F and Gandera B. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. Journal of Controlled Release 2004; 96: 437-448.
19. Bredehöft M, Schänzer W and Thevis M. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Communication in Mass Spectrometry 2008; 22: 477-485.
20. Brodniewicz T and Grynkiewicz G. Preclinical drug development. Acta Poloniae Pharmaceutica - Drug Research 2010; 67: 579-586.
21. Burana-osot J, Ungboriboonpisal S and Sriphong L. A stability-indicating HPLC method for medroxyprogesterone acetate in bulk drug and injection formulation. Journal of Pharmaceutical and Biomedical Analysis 2006; 40: 1068-1072.
22. Bush MHA, Boelens HFM, Kraak JC and Poppe H. Vacancy affinity electrophoresis, a new method for measuring association constants. Journal of Chromatography A 1997; 775: 313-326.
23. Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Natural Product Reports 2008; 25: 475-516.
24. a values of basic new drug substances by CE. Journal of Pharmaceutical and Biomedical Analysis 2001; 26: 427-434.
25. Calleri E, Temporini C and Massolini G. Frontal affinity chromatography in characterizing immobilized receptors. Journal of Pharmaceutical and Biomedical Analysis 2011; 54: 911-925.
26. Cavalli A, Salvatella X and Dobson CM, Vendruscolo M Protein structure determination from NMR chemical shifts. Proceedings of the National Academy of Science 2007; 104(23): 9615-9620.
27. Chen JZ, Han XW and Xie XQ. Preferred conformations of endogenous cannabinoid ligand anandamide. Life Science 2005; 76: 2053-2069.
28. Chen WQ, Salmazo A, Myllykoski M, Sjöblom B, Bidlingmaier M, Pollak A, Baumgärtel P, Djinovic-Carugo K, Kursula P and Lubec G. Purification of recombinant growth hormone by clear native gels for conformational analyses: preservation of conformation and receptor binding. Amino Acids 2010; 39: 859-869.
29. Chin DN, Chuaqui CE and Singh J. Integration of virtual screening into the drug discovery process. Mini-Reviews in Medicinal Chemistry 2004; 4: 1053-1065.
30. Chiu HP, Kokona B, Fairman R and Cheng RP. Effect of highly fluorinated amino acids on protein stability at a solvent-exposed position on an internal strand of protein G B1 domain. Journal of American Chemical Society 2009; 131: 13192-13193.
31. Council of Europe. Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes, 1986.
32. Council of Europe. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, 2001.
33. Council of Europe. Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products, 2005.
34. Coufal P, Štulík K, Claessens HA, Hardy MJ and Webb M. Determination of the dissociation constants of ropinirole and some impurities and their quantification using capillary zone electrophoresis. Journal of Chromatography B: Biomedical Science Application 1998; 720: 197-204.
35. Deasy B, Bogan DP, Smyth MR, O'Kennedy R and Fuhr U. Study of coumarin metabolism by human liver microsomes using capillary electrophoresis. Analytica Chimica Acta 1995; 310: 101-107.
36. Deyl Z, Mikšik I and Tagliaro F. Advances in capillary electrphoresis. Forensic Science International 1998; 92: 89-124.
37. Di L and Kerns HE. Stability challenges in drug discovery. Chemical Biodiversity 2009; 6: 1875-1886.
38. Dietz C, Sanz J and Cámarac C. Recent developments in solid-phase microextraction coatings and related techniques. Journal of Chromatography A 2006; 1103: 183-192.
39. Du QS, Huang RB and Chou KC. Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Current Protein and Peptide Science 2008; 9: 248-259.
40. Ekins S, Mestres J and Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British Journal of Pharmacology 2007; 152: 9-20.
41. Erhardt PW. Medicinal chemistry in the new millennium. A glance into the future. Pure and Applied Chemistry 2002; 74: 703-785.
42. Erny GL and Cifuentes A. Liquid separation techniques coupled with mass spectrometry for chiral analysis of pharmaceuticals compounds and their metabolites in biological fluids. Journal of Pharmaceutical and Biomedical Analysis 2006; 40: 509-515.
43. Evangelou V, Tsantili-Kakoulidou A and Koupparis M. Determination of the dissociation constants of the cephalosporins cefepime and cefpirome using UV spectrometry and pH potentiometry. Journal of Pharmaceutical and Biomedical Analysis 2003; 31: 1119-1128.
44. Ezan E, Dubois M and Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 2009; 134: 825-834.
45. Faivre S, Chièze S, Delbaldo C, Ady-vago N, Guzman C, Lopez-Lazaro L, Lozahic S, Jimeno J, Pico F, Armand JP, Lopez Martin JA and Raymond E. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. Journal of Clinical Oncology 2005; 23: 7871-7880.
46. a determination of nimesulide in methanol-water mixtures by potentiometri titrations. International Journal of Pharmaceutical Medicine 1997; 158: 109-112.
47. FDA, CDER and CVM. Guidance for Industry, Bioanalytical Method Validation. Food and Drug Administration, May 2001. Available from:.
48. Fenn JB, Mann M, Meng CK, Wong SF and Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246: 64-71.
49. Fijałek Z, Baczyński E, Piwońska A and Grześkiewicz MW. Determination of local anaesthetics and their impurities in pharmaceutical preparations using HPLC method with amperometric detection. Journal of Pharmaceutical and Biomedical Analysis 2005; 37: 913-991.
50. Finn MG 2002. Emerging methods for the rapid determination of enantiomeric excess. Chirality 14: 534-540.
51. Fiori J, Gotti R, Bertucci C and Cavrini V. Investigation on the photochemical stability of lercanidipine and its determination in tablets by HPLC-UV and LC-ESI-MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2006; 41: 176-181.
52. Frank RG. New estimates of drug development costs. Journal of Health Economics 2003; 22: 325-330.
53. Gelpì E. Biomedical and biochemical applications of liquid chromatography-mass spectrometry. Journal of Chromatography A 1995; 703: 59-80.
54. Gilpin RK and Pachla LA. Pharmaceutical and related drugs. Analytical Chemistry 2003; 75: 2907-2918.
55. Gingras AC, Aebersold R and Raught B. Advances in protein complex analysis using mass spectrometry. Journal of Physiology 2005; 563: 11-21.
56. Gluck SJ, Steele KP and Benkö MH. Determination of acidity constants of monoprotic and diprotic acids by capillary electrophoresis. Journal of Chromatography A 1996; 745: 117-125.
57. Griffin S, Wyllie GS and Markkham J. Determination of octanol-water partition coefficient for terpenoids using reversed-phase high-performance liquid chromatography. Journal of Chromatography A 1999; 864: 221-228.
58. a values of some antihypertensive drugs by liquid chromatography and simultaneous assay of lercanidipine and enalapril in their binary mixtures. Talanta 2010; 82: 1528-1537.
59. Hage DS. Chromatographic and electrophoretic studies of protein binding to chiral solutes. Journal of Chromatography A 2001; 906: 459-481.
60. Hamdan II, Jaber BAK and Abushoffa AM. Development and validation of a stability indicating capillary electrophoresis method for the determination of metformin hydrochloride in tablets. Journal of Pharmaceutical and Biomedical Analysis 2010; 53: 1254-1257.
61. Helali N, Tran NT, Monser L and Taverna M. Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals. Talanta 2008; 74: 694-698.
62. Henchoz Y, Bard B, Guillarme D, Carrupt PA, Veuthey JL and Martel S. Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution. Analytical and Bioanalytical Chemistry 2009; 394: 707-729.
63. Herbert JB and Dorsey JG. n-Octanol-water partition coefficient estimation by micellar electrokinetic capillary chromatography. Analytical Chemistry 1995; 67: 744-749.
64. Ho ENM, Wan TSM, Wong ASY, Lam KKH and Stewart BD. Doping control analysis of insulin and its analogues in equine plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A 2008; 1201: 183-190.
65. Holčapek M, Kolářová L and Nobilis M. High-performance liquid chromatography-tandem mass spectrometry in the identification of phase I and phase II drug metabolites, Analytical and Bioanalytical Chemistry 2008; 391: 59-78.
66. Hu Q, Hu G, Zhou T and Fang Y. Determination of dissociation constants of anthrocycline by capillary zone electrophoresis with amperometric detection. Journal of Pharmaceutical and Biomedical Analysis 2003; 31: 679-684.
67. ICH. Harmonized Tripartite Guideline: Studies in Support of Special Populations: Geriatrics, ICH E7. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1993.
68. ICH. Harmonized Tripartite Guideline: Dose-response Information to Support Drug Registration, ICH E4. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1994a.
69. ICH. Harmonized Tripartite Guideline: Text on Validation of Analytical Procedures, ICH Q2A. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1994b.
70. ICH. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, ICH Q5C. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996a.
71. ICH. Harmonied Tripartite Guideline: Validation of analytical procedures: methodology, ICH Q2B. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996b.
72. ICH. Harmonized Tripartite Guideline: General Considerations for Clinical Trials, ICH E8. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1997.
73. ICH. Specifications: Test Procedures And Acceptance Criteria For Biotechnological/Biological Products, ICH Q6B. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.
74. ICH. Harmonized Tripartite Guideline: Clinical Investigation of Medical Products in the Pediatric Population, ICH E11. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2000a.
75. ICH. Harmonized Tripartite Guideline: Choice of Control Group and Related Issues in Clinical Trials, ICH E10. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2000b.
76. ICH. Stability Testing Of New Drug Substances and Products, ICH Q1A (R2). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2003.
77. ICH. Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, ICH Q5E. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.
78. ICH. Harmonized Tripartite Guideline: Addendum to ICH S6: Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals, ICH S6 (R1). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009.
79. Iwai M, Hattori H, Arinobu T, Ishii A, Kumazawa T, Noguchi H, Noguchi H, Suzuki O and Seno H. Simultaneous determination of barbiturates in human biological fluids by direct immersion solid-phase microextraction and gas chromatography-mass spectrometry. Journal of Chromatography B 2004; 806: 65-73.
80. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA, Reid JM, Ames MM and Munn DH. Toxicology and pharmacokinetics of 1-methyl- d-tryptophan: absence of toxicity due to saturating absorption. Food and Chemical Toxicology 2008; 46: 203-211.
81. a values of quinolones from mobility and spectroscopic data obtained by capillary electrophoresis and a diode array detector. Analytica Chimica Acta 2002; 464: 37-45.
82. Joubert PH. Dose optimization in drug development: role of phase 4 trials. International Congress Series 2001; 1220: 51-65.
83. Jouyban A, Fakhree AAM and Shayanfar A. Solubility prediction methods for drug/drug like molecules. Recent Patents on Chemical Engineering 2008; 1: 220-231.
84. Kanazawa H, Atsumi R, Matsushima Y and Kizu J. Determination of theophylline and its metabolites in biological samples by liquid chromatography-mass spectrometry, Journal of Chromatography A 2000; 870: 87-96.
85. Kašička V. Recent developments in CE and CEC of peptides. Electrophoresis 2008; 29: 179-206.
86. Kataoka H and Saito K. Recent advances in SPME techniques in biomedical analysis. Journal of Pharmaceutical and Biomedical Analysis 2011; 54: 926-950.
87. Kaul N, Agrawal H, Paradkar AR and Mahadik KR. HPTLC method for determination of nevirapine in pharmaceutical dosage form. Talanta 2004; 62: 843-852.
88. Kawaoka J and Gomez FA. Use of mobility ratios to estimate binding constants of ligands to proteins in affinity capillary electrophoresis. Journal of Chromatography B 1998; 715: 203-210.
89. Kennedy TK. Bioanalytical applications of fast capillary electrophoresis. Analytica Chimica Acta 1999; 400: 163-180.
90. Khoschsorur G, Erwa W, Fruehwirth F, Stettin M, Meinitzer A, Hoebarth G, Zelzer S and Halwachs-Baumann G. High-performance liquid chromatographic method for the simultaneous determination of cyclosporine A and its four major metabolites in whole blood. Talanta 2005; 65: 638-643.
91. Kim SH and Wainer IW. Rapid analysis of the interactions between drugs and human serum albumin (HSA) using high-performance affinity chromatography (HPAC). Journal of Chromatography B: Analytical and Biomedical Life Science 2008; 870: 22-26.
92. Kollipara S, Bende G, Agarwal N, Varshney B and Paliwal J. International guidelines for bioanalytical method validation: a comparison and discussion on current scenario. Chromatographia 2011; 73: 201-217.
93. Korfmacher WA. Principles and applications of LC-MS in new drug discovery. Drug Discovery Today 2005; 10(20): 1357-1367.
94. Koster EHM, Wemes C, Morsink JB and de Jong GJ. Determination of lidocaine in plasma by direct solid-phase microextraction combined with gas chromatography. Journal of Chromatography B: Biomedical Science Applications 2000; 739: 175-182.
95. Kostiainen R, Kotiaho T, Kuuranne T and Auriola S. Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. Journal of Mass Spectrometry 2003; 38: 357-372.
96. Krishna Reddy KVSR, Moses Babu J, Mathad VT, Eswaraiah S, Satyanarayana Reddy M, Dubey PK and Vyas V. Impurity profile study of repaglinide. Journal of Pharmaceutical and Biomedical Analysis 2003; 32: 461-467.
97. Kulkarni SP and Amin PD. Stability indicating HPTLC determination of timolol maleate as bulk drug and in pharmaceutical preparations. Journal of Pharmaceutical and Biomedical Analysis 2000; 23: 983-987.
98. Lai EPC and Feng SY. Solid phase extraction - non-aqueous capillary electrophoresis for determination of metformin, phenformin and glyburide in human plasma. Journal of Chromatography B 2006; 843: 94-99.
99. Lakshmana PS and Suriyaprakash TNK. Impurities and its importance in pharmacy. International Journal of Pharmaceutical Sciences Review and Research 2010; 3(2): 66-71.
100. Le Breton MH, Beck-Henzelin A, Richoz-Payot J, Rochereau-Roulet S, Pinel G, Delatour T and Le Bizec B. Detection of recombinant bovine somatotropin in milk and effect of industrial processes on its stability. Analytica Chimica Acta 2010; 672: 45-49.
101. Lee IS and Hufford CD. Metabolism of antimalarial sesquiterpene lactones. Pharmacology Therapeutics 1990; 48: 345-355.
102. Lee JW and Colburn WA. Immunoassay techniques. In Handbook of Pharmaceutical Analysis, Ohannesian L, Streeter AJ (eds). Marcel Dekker: New York, 2002; 225-312.
103. Lee VHL. Changing needs in drug delivery in the era of peptide and protein drugs. In Peptide and Protein Drug Delivery, Lee VHL (ed.). Marcel Dekker: New York; 1991; 1-56.
104. Leis HJ, Fauler G, Raspotnig G and Windischhofer W. Quantitative analysis of morphine in human plasma by gas chromatography-negative ion chemical ionization mass spectrometry, Journal of Chromatography B: Biomedical Science Applications 2000; 744: 113-119.
105. Lepre AC and Peng JW. Theory and applications of NMR-based screening in pharmaceutical research. Chemical Review 2004; 104: 3641-3675.
106. Liang Y, Denton MB and Bates RB. Stability studies of tetracycline in methanol solution. Journal of Chromatography A 1998; 827: 45-55.
107. Lim CK and Lord G. Current development in LC-MS for pharmaceutical analysis. Biological and Pharmaceutical Bulletin 2002; 25: 547-557.
108. Locatelli M. Anthraquinones: analytical techniques as a novel tool to investigate on the triggering of biological targets. Current Drug Targets 2011; 12: 366-380.
109. Locatelli M and Carlucci G. Advanced capillary electrophoresis techniques in the analytical quantification of drugs, metabolites and biomarkers in biological samples. Global Journal of Analytical Chemistry 2010; 1: 244-261.
110. Lucangioli SE, Kenndler E, Carlucci A, Tripodi VP, Scioscia SL and Carducci CN. Relation between retention factors of immunosuppressive drugs in microemulsion electrokinetic chromatography with biosurfactants and octanol-water partition coefficients. Journal of Pharmaceutical and Biomedical Analysis 2003; 33: 871-878.
111. Mahmood I. Methods to determine pharmacokinetic profiles of therapeutic proteins. Drug Discovery Today: Technologies 2008; 5: e65-e69.
112. Mahmood I and Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clinical Pharmacokinetics 2005; 44: 331-347.
113. Makarov A and Scigelova M. Coupling liquid chromatography to Orbitrap mass spectrometry. Journal of Chromatography A 2010; 1217: 3938-3945.
114. Mandrioli R, Musenga A, Kenndler E, De Donno M, Amore M and Raggi MA. Determination of topiramate in human plasma by capillary electrophoresis with indirect UV detection. Journal of Pharmaceutical and Biomedical Analysis 2010; 53: 1319-1323.
115. Manning MC, Chou DK, Murphy BM, Payne RW and Katayama DS 2010. Stability of protein pharmaceuticals: an update. Pharmacy Research Archives 2010; 27: 544-575.
116. Martìnez-Gómez MA, Carril-Avilès MM, Segrado S, Villanueva-Camañas RM and Medina-Hernández MJ. Characterization of antihistamine-human serum protein interactions by capillary electrophoresis. Journal of Chromatography A 2007; 1147: 261-269.
117. Maurer HH. Multi-analyte procedures for screening for and quantification of drugs in blood, plasma or serum by liquid-chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology. Clinical Biochemistry 2005; 38: 310-315.
118. Mazák K, Vámos J, Nemes A, Rácz A and Noszál B. Lipophilicity of vinpocetine and related compounds characterized by reversed-phase thin-layer chromatography. Journal of Chromatography A 2003; 996: 195-203.
119. Meyer B and Peters T. NMR Spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angewandte Chemie International Edition 2003; 42: 864-890.
120. Mirmehrabi M, Rohani S and Murthy KSK, Radatus B. Solubility, dissolution rate and phase transition studies of ranitidine hydrochloride tautomeric forms. International Journal of Pharmacology 2004; 282: 73-85.
121. Motwani SK, Khar RK, Ahmad FJ, Chopra S, Kohli K and Talegaonkar S. Application of a validated stability-indicating densitometric thin-layer chromatographic method to stress degradation studies on moxifloxacin. Analytica Chimica Acta 2007; 582: 75-82.
122. Nelson RW, Krone JR, Bieber AL and Williams P. Mass spectrometric immunoassay. Analytical Chemistry 1995; 67: 1 153-1158.
123. Newcomb R, Abbruscato TJ, Singh T, Nadasdi L, Davis TP and Miljanich G. Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion. Peptides 2000; 21: 491-501.
124. Niederländer HAG, Koster EHM, Hilhorst MJ, Metting HJ, Eilders M, Ooms B and de Jong GJ. High throughput therapeutic drug monitoring of clozapine and metabolites in serum by on-line coupling of solid phase extraction with liquid chromatography-mass spectrometry. Journal of Chromatography B 2006; 834: 98-107.
125. O'Byrne PM, Williams R, Walsh JJ and Gilmer JF. The aqueous stability of bupropion. Journal of Pharmaceutical and Biomedical Analysis 2010; 53: 376-381.
126. Oertel R, Richter K, Gramattè T and Kirch, W. Determination of drugs in biological fluids by high-performance liquid chromatography with on-line sample processing. Journal of Chromatography A 1998; 797: 203-209.
127. Örnskov E. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 947: Physicochemical and Biopharmaceutical Characterization of Small Drug Molecules by Capillary Electrophoresis. Acta Universitatis Upsaliensis, Uppsala 2004.
128. Örnskov E, Linusson A and Folestad S. Determination of dissociation constants of labile drug compounds by capillary electrophoresis, Journal of Pharmaceutical and Biomedical Analysis 2003; 33: 379-391.
129. Pandey R, Singh AV, Pandey A, Tripathi P, Majumdar SK and Nath LK. Protein and peptide drugs: a brief review. Research Journal of Pharmaceutical Technology 2009; 22: 228-233.
130. Pang H, Kenseth J and Coldiron S. High-throughput multiplexed capillary electrophoresis in drug discovery. Drug Discovery Today 2004; 9(24): 1072-1080.
131. Papoutsis II, Athanaselis SA, Nikolaou PD, Pistos CM, Spiliopoulou CA and Maravelias CP. Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology. Journal of Pharmaceutical and Biomedical Analysis 2010; 52: 609-614.
132. Patravale VB, Nair VB and Gore SP. High performance thin layer chromatographic determination of nifedipine from bulk drug and from pharmaceuticals. Journal of Pharmaceutical and Biomedical Analysis 2000; 23: 623-627.
133. Pavli V and Kmetec V. Optimization of HPLC method for stability testing of bacitracin. Journal of Pharmaceutical and Biomedical Analysis 2001; 24: 977-982.
134. Pillai O. Drug delivery: an odyssey of 100years. Current Opinion in Chemical Biology 2001; 5: 439-446.
135. Pinnow E, Pellavi S, Parekh A, Gevorkian N and Uhl K. Increasing participation of women in early phase clinical trials approved by the FDA. Women's Health Issues 2009; 19: 89-93.
136. Pisal DS, Kosloski MP and Balu-Iyer SV. Delivery of therapeutic proteins. Journal of Pharmaceutical Science USA 2010; 99: 2557-2575.
137. Pistos C, Panderi I and Politou JA. Liquid chromatography-positive ion electrospray mass spectrometry method for the quantification of citalopram in human plasma. Journal of Chromatography B 2004; 810: 235-244.
138. Poole SK and Poole CF. Separation methods for estimation octanol-water partition coefficients. Journal of Chromatography B 2003; 797: 3-19.
139. Poole SK, Dehring K, Workman H and Poole CF. Determination of acid dissociation constants by capillary electrophoresis. Journal of Chromatography A 2004; 1037: 445-454.
140. Qian H, Gu Y, Wang M and Achilefu S. Optimization of the near-infrared fluorescence labeling for in vivo monitoring of a protein drug distribution in animal model. Journal of Fluorescence 2009; 19: 277-284.
141. Qin F, Ma Y, Wang Y, Chen L, Wang D and Li F. Determination of nimodipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and pharmacokinetic application. Journal of Pharmaceutical and Biomedical Analysis 2008; 46: 557-562.
142. Ragehy NAE, Badawey AM and Khateeb SZE. Stability indicating methods for the determination of loratadine in the presence of its degradation product. Journal of Pharmaceutical and Biomedical Analysis 2002; 28: 1041-1053.
143. Ramakrishnan R, Cheung WK, Farrell F, Joffee L and Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. Journal of Pharmacology and Experimental Therapeutics 2003; 306: 324-331.
144. Rao NR and Nagaraju V. An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. Journal of Pharmaceutical and Biomedical Analysis 2003; 32: 335-377.
145. Reichert JM. Trends in development and approval times for new therapeutics in United States. Natural Review Drug Discovery 2003; 2: 695-702.
146. Roberts GCK. Applications of NMR in drug discovery. Drug Discovery Today 2000; 5(6): 230-240.
147. Robiner WN. Enhancing adherence in clinical research. Contemporary Clinical Trials 2005; 26: 59-77.
148. Ryan R, Donegan S, Power J and Altria K. Advances in the theory and application of MEEKC. Electrophoresis 2010; 31: 755-767.
149. 13C NMR of lisinopril. Journal of Molecular Structure 1993; 298: 129-136.
150. Samanidou VF, Evaggelopoulou EN and Papadoyannis IN. Simultaneous determination of quinine and chloroquine anti-malarial agents in pharmaceuticals and biological fluids by HPLC and fluorescence detection. Journal of Pharmaceutical and Biomedical Analysis 2005; 38: 21-28.
151. Schiel JE, Ohnmacht CM and Hage DS. Measurement of drug-protein dissociation rates by high-performance affinity chromatography and peak profiling. Analytical Chemistry 2009; 81: 4320-4333.
152. Sekhon BS. Biopharmaceuticals: an overview. Thai Journal of Pharmaceutical Science 2010; 34: 1-19.
153. Shaikh SA, Jain T, Sandhu G, Latha N and Jayaram B. From drug target to leads - sketching a physicochemical pathway for lead molecule design in silico. Current Pharmaceutical Design 2007; 13: 3454-3470.
154. a values) of organic compound by multiplexed capillary electrophoresis using aqueous and cosolvent buffers. Journal of Pharmaceutical Science USA 2008; 97: 2581-2606.
155. Shibukawa A, Kuroda Y and Nakagawa T. High-performance frontal analysis for drug-protein binding study. Journal of Pharmaceutical and Biomedical Analysis 1999; 18: 1047-1055.
156. Shibukawa A, Rodriguez Rosas ME and Nakagawa T. Application of high-performance frontal analysis to enantioselective studies on drug-plasma protein binding. Chromatography 2001; 22(1): 25-31.
157. Shibukawa A, Ishizawa N, Kimura T, Sakamoto Y, Ogita K, Matsuo Y, Kuroda Y, Matayatsuk C, Nakagawa T and Wainer IW. Plasma protein binding study of oxybutynin by high-performance frontal analysis. Journal of Chromatography B: Analytical Technology and Biomedical Life Science 2002; 768: 177-188.
158. Sidelmann UG, Bjørnsdottir I, Shockcor JP, Hansen SH, Lindon JC and Nicholson JK. Directly coupled HPLC-NMR and HPLC-MS approaches for the rapid characterisation of drug metabolites in urine: application to the human metabolism of naproxen. Journal of Pharmaceutical and Biomedical Analysis 2001; 24: 569-579.
159. a of nimesulide. International Journal of Pharmaceutics 1999; 176: 261-264.
160. Sirén H, Seppänen-Laakso T and Orešič M. Capillary electrophoresis with UV detection and mass spectrometry in method development for profiling metabolites of steroid hormone metabolism. Journal of Chromatography B 2008a; 871: 375-382.
161. Sirén H, Shimmo R, Sipola P, Abenet S and Riekkola ML. Capillary electrophoresis of diuretics and probenecid in methanol. Journal of Chromatography A 2008b; 1198-1199: 215-219.
162. Solá RJ and Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. Journal of Pharmaceutical Science USA 2009; 98: 1223-1245.
163. Soltanpour Sh and Jouyban A. Solubility of acetaminophen and ibuprofen in polyethylene glycol 600, propylene glycol and water mixtures at 25°C. Journal of Molecular Liquids 2010; 155: 80-84.
164. Soman S, Yoo MJ, Jang YJ and Hage DS. Analysis of lidocaine interactions with serum proteins using high-performance affinity chromatography. Journal of Chromatography B 2010; 878: 705-708.
165. Stockman BJ and Dalvit C 2002. NMR screening techniques in drug discovery and drug design. Progress in Nuclear Magnetic Resonance Spectroscopy 41: 187-231.
166. Streel B, Lainé C, Sibenaler R and Ceccato A. Enantiomeric determination of amlodipine in human plasma by liquid chromatography coupled to tandem mass spectrometry. Journal of Biochemical and Biophysics Methods 2002; 54: 357-368.
167. Suntornsuk L. Recent advances of capillary electrophoresis in pharmaceutical analysis. Analytical and Bioanalytical Chemistry 2010; 398: 29-52.
168. Szabelski P and Kaczmarski K. Phenomenological modeling of separation of enantiomers by nonlinear chromatography. Acta Chromatographia 2008; 20: 513-547.
169. Tamaro I, Aprile S, Giovenzana GB and Grosa G. Development and validation of a stability-indicating HPLC-UV method for the determination of alizapride and its degradation products. Journal of Pharmaceutical and Biomedical Analysis 2010; 51: 1024-1031.
170. Tanaka Y and Terabe S. Estimation of binding constants by capillary electrophoresis. Journal of Chromatography B 2002; 768: 81-92.
171. Tang L, Persky AM, Hochhaus G and Meibohm B. Pharmacokinetic aspects of biotechnology products. Journal of Pharmaceutical Science USA 2004; 93: 2184-2204.
172. Theodoridis G. Application of solid-phase microextraction in the investigation of protein binding of pharmaceuticals. Journal of Chromatography B 2006; 830: 238-244.
173. Tomlinson AJ, Benson LM, Johnson KL and Naylor S. Investigation of the metabolic fate of the neuroleptic drug haloperidol by capillary electrophoresis-electrospray ionization mass spectrometry. Journal of Chromatography B: Biomedical Science Applications 1993; 621: 239-248.
174. Tubbs KA, Kiernan UA, Niederkofler EE, Nedelkov D, Bieber AL and Nelson RW. Development of recombinant-based mass spectrometric immunoassay with application to resistin expression profiling. Analytical Chemistry 2006; 78: 3271-3276.
175. Tulp M and Bohlin L. Unconventional natural sources for future drug discovery. Drug Discovery Today 2004; 9(10): 450-458.
176. Ulrich S. Solid-phase microextraction in biomedical analysis. Journal of Chromatography A 2000; 902: 167-194.
177. Upmanyu N, Garg G, Dolly A and Mishra P. Nuclear magnetic resonance spectroscopy: an evolutionary approach to drug design. e-Journal of Chemistry 2007; 4: 294-301.
178. Varley PG, Brown AJ, Dawkes HC and Burns NR. A case study and use of sedimentation equilibrium analytical ultracentrifugation as a tool for biopharmaceutical development. European Biophysics Journal 1997; 25: 437-443.
179. Vas G and Vékey K. Solid-phase microextraction: a powerful sample preparation tool prior to mass spectrometric analysis. Journal of Mass Spectrometry 2004; 39: 233-254.
180. Vuignier K, Schappler J, Veuthey JL, Carrupt PA and Martel S. Drug-protein binding: a critical review of analytical tools. Analytical and Bioanalytical Chemistry 2010; 398: 53-66.
181. Vukušić I. Thin-layer chromatographic determination of betamethasone dipropionate in semi-solid pharmaceutical preparations. Journal of Chromatography A 1982; 243: 131-138.
182. Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends in Biotechnology 2005; 23: 553-558.
183. Wang Q, Ma D and Higgins JP. Analytical method selection for drug product dissolution testing. Dissolution Technology 2006; 13: 6-13.
184. Waser PG, Bodmer DM and Hopff WH. Isolation and purification of acetylcholine receptor proteins by affinity chromatography. European Journal of Pharmacology: Molecular Pharmacology 1989; 172: 231-238.
185. Watts A. NMR of drugs and ligands bound to membrane receptors. Current Opinion in Chemical Biology 1999; 10: 48-53.
186. Wu X, Gong S, Bo T, Liao Y and Liu H. Determination of dissociation constants of pharmacologically active xanthones by capillary zone electrophoresis with diode array detection. Journal of Chromatography A 2004; 1061: 217-223.
187. Yang E, Wang S, Kratz J and Cyronak MJ. Stereoselective analysis of carvedilol in human plasma using HPLC/MS/MS after chiral derivatization. Journal of Pharmaceutical and Biomedical Analysis 2004; 36: 609-615.
188. Yang Z, Peng Y and Wang S. Immunosuppressants: Pharmacokinetics, methods of monitoring and role of high performance liquid chromatography/mass spectrometry. Clinical and Applied Immunology Reviews 2005; 5: 405-430.
189. Yang Z, Hayes M, Fang X, Daley MP, Ettenberg S and Tse FLS. LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. Analytical Chemistry 2007; 79: 9294-9301.
190. Yang Z and Wang S. Recent development in application of high performance liquid chromatography-tandem mass in therapeutic drug monitoring of immunosuppressants. Journal of Immunology Methods 2008; 336: 98-103.
191. Zhang MQ and Wilkinson B. Drug discovery beyond the 'rule-of-five'. Current Opinion in Biotechnology 2007; 18: 478-488.
192. Zhongjiang J, Ramstad T and Zhong M. Determination of protein-drug binding constants by pressure-assisted capillary electrophoresis (PACE)/frontal analysis (FA). Journal of Pharmaceutical and Biomedical Analysis 2002; 30: 405-413.
193. Zhou D and Li F. Protein binding study of clozapine by capillary electrophoresis in the frontal analysis mode. Journal of Pharmaceutical and Biomedical Analysis 2004; 35: 879-885.